$BMY

Generating a unique summary for BMY…

AI-generated for information only — not investment advice.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Institutions hold 85.02% · insiders 0.10% · 3,275 institutions

Consensus score 2.46 (1 = strong buy, 5 = sell) · mean target 66.21

• Argus ResearchBuyup2026-08-05
• CitigroupNeutralmain2026-08-03
• RBC CapitalSector Performmain2026-07-31
• JP MorganOverweightmain2026-07-31
• Cantor FitzgeraldNeutralmain2026-07-31
• Wells FargoEqual-Weightmain2026-07-31
• GuggenheimBuymain2026-07-31
• Truist SecuritiesBuyreit2026-07-31
• B of A SecuritiesBuymain2026-07-10
• Cantor FitzgeraldNeutralreit2026-07-06

Next report: 2026-10-29

• 10-QPeriodic Financial Reports2026-07-30Open
• 11-KAnnual report of employee stock purchase2026-06-05Open
• 8-KCorporate Changes & Voting Matters2026-05-08Open
• 8-KCorporate Changes & Voting Matters2026-04-30Open
• DEFA14AProxy Statements2026-04-17Open
• 15-12GNotice of termination of registration of a class of securities under Section 12(g)2026-03-27Open
• DEF 14AProxy Statements2026-03-25Open
• 10-KPeriodic Financial Reports2026-02-11Open
• 8-KCorporate Changes & Voting Matters2026-02-05Open
• 8-KCorporate Changes & Voting Matters2026-01-12Open

• Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

  In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.

  Fri, 04 Sep 2026 21:45:03 +0000

• Sector Update: Healthcare Stocks Decline Late Afternoon

  Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and

  Fri, 04 Sep 2026 19:48:43 +0000

• Sector Update: Healthcare Stocks Decline Friday Afternoon

  Healthcare stocks were lower Friday afternoon, with the NYSE Healthcare Index and the State Street H

  Fri, 04 Sep 2026 17:41:05 +0000

• Market Chatter: Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns

  Bristol Myers Squibb (BMY) has told regulators, researchers and patient groups in early June that it

  Fri, 04 Sep 2026 09:10:29 +0000

• Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

  Despite Bristol-Myers Squibb's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

  Thu, 03 Sep 2026 15:39:52 +0000

• Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds

  Program yields evidence supporting $14.1 million in savings by keeping patients out of the hospitalALEXANDRIA, VA / ACCESS Newswire / September 3, 2026 / Originally published on NCPA.

  Thu, 03 Sep 2026 13:00:00 +0000

• What Does Bristol Myers Squibb (BMY) Trial Pause Mean For Its Pipeline?

  Bristol Myers Squibb (NYSE:BMY) has paused enrollment in its zola-cel cell therapy trials for autoimmune conditions following emerging safety concerns. The voluntary pause comes after inflammatory side effects were detected during ongoing safety surveillance in the program. The move raises fresh questions around the risk profile of cell-based therapies in autoimmune diseases, as well as the pace of Bristol Myers Squibb's clinical pipeline. For readers interested in more ideas in this corner...

  Thu, 03 Sep 2026 04:31:19 +0000

• Bristol Myers Squibb (BMY) Gains On Camzyos Data, Is The Upside Already Priced In?

  Bristol-Myers Squibb (BMY) is back in focus after presenting long term Camzyos data from the EXPLORER-LTE cohort at the 2026 European Society of Cardiology Congress in Munich. Against this backdrop, Bristol-Myers Squibb’s share price has moved to US$66.92, with a 90 day share price return of 22.3% and a year to date share price return of 25.2%, while the 1 year total shareholder return of 47.9% points to stronger gains once dividends are included. Recent momentum has coincided with strong Q2...

  Wed, 02 Sep 2026 15:07:03 +0000